Xcout IntelDefinium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Subscribe to see Definium Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Definium Therapeutics, Inc. at a glance
Definium Therapeutics, Inc. is a biotech company headquartered in New York, United States. It is publicly listed (DFTX) with a market capitalisation of $4.9B. Xcout tracks 23 named people at Definium Therapeutics, Inc., including Robert Barrow (Chief Executive Officer & Director). Xcout recorded 77 job postings from Definium Therapeutics, Inc. in the last 90 days, naming tools such as Coupa, NetSuite.
Definium Therapeutics, Inc. leadership
- Robert BarrowChief Executive Officer & Director
- Brandi L. RobertsChief Financial Officer
- Brandi RobertsChief Financial Officer
- Daniel Rollings KarlinChief Medical Officer
- Mark R. SullivanChief Legal Officer & Corporate Secretary
- Daniel R. KarlinChief Medical Officer
17 more named people on record for Definium Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Definium Therapeutics, Inc.
Xcout recorded 77 job postings from Definium Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Definium Therapeutics, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Definium Therapeutics, Inc.'s hiring signals →
Hiring vs the trend
Based on 35 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 158 scale-up healthcare companies.
This describes a hiring pattern — how often Definium Therapeutics, Inc.’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
Definium Therapeutics, Inc. competitors
A few of Definium Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
AtaiBeckley Inc. has its corporate headquarters located in New York, USA. The biopharmaceutical company is on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments.
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Get Definium Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Definium Therapeutics, Inc. in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access